BCR-ABL expression and phosphorylation, as well as downstream targets expression important in CML growth and survival, were all inhibited by MAKV-8-imatinib combination (Lernoux et al., 2020). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.